Get started
Author

Kei Koizumi

Human Breast Cancer Tissues Contain Abundant Phosphatidylcholine(36∶1) with High Stearoyl-CoA Desaturase-1 Expression
2013 · Yoshimi Ide, Michihiko Waki, et al. · PLoS ONE · 139
PDF
Increased Polyamine Intake Inhibits Age-Associated Alteration in Global DNA Methylation and 1,2-Dimethylhydrazine-Induced Tumorigenesis
2013 · Kuniyasu Soda, Yoshihiko Kano, et al. · PLoS ONE · 107
PDF
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition
2020 · Tatsunori Shimoi, Shigenori E. Nagai, et al. · Breast Cancer · 73
PDF
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition
2023 · Mitsuo Terada, Aki Ito, et al. · Breast Cancer · 64
PDF
DNA methylation alterations of AXIN2 in serrated adenomas and colon carcinomas with microsatellite instability
2014 · Yuta Muto, Takafumi Maeda, et al. · BMC Cancer · 32
PDF
Array-based identification of common DNA methylation alterations in ulcerative colitis
2011 · KEI KOIZUMI, SERGIO ALONSO, et al. · International Journal of Oncology · 25
PDF
Correction: Human Breast Cancer Tissues Contain Abundant Phosphatidylcholine(36∶1) with High Stearoyl-CoA Desaturase-1 Expression
2013 · Yoshimi Ide, Michihiko Waki, et al. · PLoS ONE · 23
PDF
Lipidomics-based tissue heterogeneity in specimens of luminal breast cancer revealed by clustering analysis of mass spectrometry imaging: A preliminary study
2023 · Shuhei Aramaki, Shogo Tsuge, et al. · PLoS ONE · 20
PDF
Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
2020 · Toshinari Yamashita, Norikazu Masuda, et al. · Trials · 17
PDF
Preoperative concurrent endocrine therapy with chemotherapy in luminal B-like breast cancer
2020 · Ryoichi Matsunuma, Toru Watanabe, et al. · Breast Cancer · 16
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial
2025 · Toshinari Yamashita, Shigehira Saji, et al. · Journal of Clinical Oncology · 15
PDF
Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results
2018 · Katsuhiko Nakatsukasa, Hiroshi Koyama, et al. · Breast Cancer · 14
Two cases of diabetic mastopathy: MR imaging and pathological correlation
2012 · Hatsuko Nasu, Akiko Ikeda, et al. · Breast Cancer · 13
Ubiquitin-like 3 as a new protein-sorting factor for small extracellular vesicles
2022 · Yusuke Takanashi, Tomoaki Kahyo, et al. · Cell Structure and Function · 12
PDF
A difficult-to-diagnose fibromatosis-like metaplastic carcinoma of the breast: a case report
2021 · Daiki Takatsuka, Hiroyuki Ogura, et al. · Surgical Case Reports · 12
PDF
Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
2020 · Toshinari Yamashita, Norikazu Masuda, et al. · Trials · 10
PDF
Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer
2019 · Koichi Sakaguchi, Hisako Ono, et al. · Medicine · 8
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor–positive, HER2-negative advanced or metastatic breast cancer
2025 · Tetsuhiro Yoshinami, Yuko Takano, et al. · Breast Cancer · 5
PDF
Status of incremental costs of first-line treatment recommended in Japanese clinical guidelines for metastatic breast cancer patients
2024 · Tsuguo Iwatani, Keita Sasaki, et al. · Japanese Journal of Clinical Oncology · 5
PDF
UBL3 overexpression enhances EV-mediated Achilles protein secretion in conditioned media of MDA-MB-231 cells
2024 · Mst. Afsana Mimi, Md. Mahmudul Hasan, et al. · Biochemical and Biophysical Research Communications · 5
PDF
Dose-dense adjuvant chemotherapy: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2018 edition
2020 · Tetsuhiro Yoshinami, Kei Koizumi, et al. · Breast Cancer · 4
A Case of Castleman Disease in Lesser Omentum Removed by Laparoscopic Operation
2008 · Tadahiro ISONO, Toshihiko KOBAYAHI, et al. · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) · 3
PDF
Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 − advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26)
2025 · Hiroko Bando, Aya Ueda, et al. · Breast Cancer · 2
PDF
Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition
2021 · Tatsunori Shimoi, Shigenori E. Nagai, et al. · Breast Cancer · 2
PDF
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II)
2024 · Kenichi Suzuki, Takashi Yokokawa, et al. · Scientific Reports · 1
Works count: 41
Citation count: 629
H-index: 13
I10-index: 16
Year
Topic
Type